Last reviewed · How we verify

PEGylated recombinant candida urate oxidase

Shenyang Sunshine Pharmaceutical Co., LTD. · Phase 1 active Small molecule

PEGylated recombinant candida urate oxidase is a Small molecule drug developed by Shenyang Sunshine Pharmaceutical Co., LTD.. It is currently in Phase 1 development. Also known as: SSS11.

At a glance

Generic namePEGylated recombinant candida urate oxidase
Also known asSSS11
SponsorShenyang Sunshine Pharmaceutical Co., LTD.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PEGylated recombinant candida urate oxidase

What is PEGylated recombinant candida urate oxidase?

PEGylated recombinant candida urate oxidase is a Small molecule drug developed by Shenyang Sunshine Pharmaceutical Co., LTD..

Who makes PEGylated recombinant candida urate oxidase?

PEGylated recombinant candida urate oxidase is developed by Shenyang Sunshine Pharmaceutical Co., LTD. (see full Shenyang Sunshine Pharmaceutical Co., LTD. pipeline at /company/shenyang-sunshine-pharmaceutical-co-ltd).

Is PEGylated recombinant candida urate oxidase also known as anything else?

PEGylated recombinant candida urate oxidase is also known as SSS11.

What development phase is PEGylated recombinant candida urate oxidase in?

PEGylated recombinant candida urate oxidase is in Phase 1.

Related